Batiraxcept for Fallopian Tube Carcinoma
This trial is testing the side effects and best dose of AVB-S6-500 in combination with durvalumab for patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back.
- Fallopian Tube Carcinoma
- Peritoneal Carcinoma
- Fallopian Tube Cancer
- Ovarian Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many participants have consented to this clinical trial?
"At present, this medical trial is not presently enrolling patients. The clinical trial was first listed on October 11th 2019 and the latest update occurred on December 8th 2022. There are currently 3693 studies recruiting for recurrent ovarian carcinoma, as well as 334 trials actively seeking participants to test out Batiraxcept."
Have there been prior investigations utilizing Batiraxcept?
"Currently, there are 334 active clinical trials with 51 of those in the final Phase 3 stage. Although most studies for Batiraxcept originate from Nashville, Tennessee, this drug is being explored at 12994 different sites worldwide."
How has Batiraxcept been implemented as a treatment option?
"Batiraxcept is a common treatment for stage 3 unresectable non-small cell lung cancer. Additionally, it has been employed to treat metastatic ureteral carcinoma and advanced directives."
Are there any openings to participate in this experiment?
"Clinicaltrials.gov attests that the posted trial, which was established in October 2019 and updated last December, is not accepting applicants presently. However, there are still plenty of other medical trials available with 4027 being open for recruitment."